Balentine LLC’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Balentine LLC’s Portfolio LJPC Stock Details LJPC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-150	Closed	-$1K	–	969
2020 Q1	$1K	Buy	+150	New	+$947	﹤0.01%	653

Other funds holding LJPC

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Balentine LLC's LJPC Position: Q2 2020 in Review

Balentine LLC sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2020, closing a stake of 150 shares — an estimated $1K sold.

Balentine LLC first reported a position in LJPC in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 76 funds tracked by Wall St. Rank hold LJPC as of Q2 2020.

Balentine LLC reported no remaining La Jolla Pharmaceutical Company position as of Q2 2020 after selling out during the quarter.
Balentine LLC sold 150 La Jolla Pharmaceutical Company shares in Q2 2020, an estimated $1K.
Balentine LLC first reported a position in La Jolla Pharmaceutical Company in Q1 2020 and held it in 1 quarter.
Balentine LLC's La Jolla Pharmaceutical Company position peaked at $1K in Q1 2020.
76 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2020.

Based on Balentine LLC's 13F filing for Q2 2020, filed 14 Aug 2020.